Insider Selling: Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Sells $26,800.00 in Stock

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.34, for a total value of $26,800.00. Following the transaction, the insider now directly owns 24,070,521 shares of the company’s stock, valued at approximately $32,254,498.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, January 27th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.52, for a total value of $30,400.00.
  • On Tuesday, January 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.90, for a total value of $38,000.00.
  • On Monday, January 13th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.64, for a total value of $32,800.00.
  • On Monday, January 6th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.47, for a total value of $29,400.00.
  • On Monday, December 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.07, for a total value of $21,400.00.
  • On Monday, December 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.97, for a total value of $19,400.00.
  • On Monday, December 16th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.05, for a total value of $21,000.00.
  • On Monday, December 9th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.08, for a total value of $21,600.00.
  • On Monday, December 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.14, for a total value of $22,800.00.
  • On Monday, November 25th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.13, for a total value of $22,600.00.

Shares of NASDAQ:TYME opened at $1.25 on Friday. Tyme Technologies Inc has a 52-week low of $0.92 and a 52-week high of $3.42. The firm has a market capitalization of $156.01 million, a P/E ratio of -5.21 and a beta of 0.40. The stock has a 50 day moving average price of $1.51 and a 200-day moving average price of $1.30.

Several large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Tyme Technologies by 5.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock worth $374,000 after acquiring an additional 17,173 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Tyme Technologies by 77.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 142,500 shares of the company’s stock worth $170,000 after acquiring an additional 62,000 shares in the last quarter. Morgan Stanley raised its position in shares of Tyme Technologies by 187.8% in the 2nd quarter. Morgan Stanley now owns 139,579 shares of the company’s stock worth $170,000 after acquiring an additional 91,081 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Tyme Technologies in the 3rd quarter worth approximately $71,000. Finally, Barclays PLC raised its position in shares of Tyme Technologies by 102.1% in the 4th quarter. Barclays PLC now owns 59,040 shares of the company’s stock worth $83,000 after acquiring an additional 29,821 shares in the last quarter. 12.92% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $9.50 target price on shares of Tyme Technologies in a research report on Thursday, February 6th. Zacks Investment Research lowered Tyme Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, January 11th.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: Dividend Reinvestment Plan (DRIP)

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.